AI biotech company Owkin announced a partnership with pharma giant AstraZeneca to develop an AI-powered tool designed to prescreen for gBRCA mutations (gBRCAm) in breast cancer directly from digitized pathology slides.
According to Owkin, BRCA testing, which identifies mutations in the BRCA1 and BRCA2 genes, plays an important role in deciding a person's risk for developing certain cancers,...
